Acticor Biotech Announces Its Financial Calendar for the 1st Half of 2024
25.01.2024 - Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announced today its financial agenda for the 1st half of ...
Source: wallstreet-online.de